Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab therapy in patients with hepatocellular carcinoma.

Katsuya ToshidaShinji ItohShohei YoshiyaYoshihiro NagaoTakahiro TominoTakuma IzumiNorifumi IsedaTakeo ToshimaMizuki NinomiyaTomoharu Yoshizumi

Published in: Journal of gastroenterology and hepatology (2023)

A high pretreatment eosinophil count predicted a better response to ATZ/BEV therapy for u-HCC and was associated with the incidence of AEs (≥ grade 3).

Keyphrases

peripheral blood
risk factors